## **Special Issue**

# Insights into Psychiatric Disorders from a Neuroimaging Perspective

#### Message from the Guest Editor

This Special Issue of *Biomedicines* aims to provide a suitable forum to tackle such challenges. We are eager to foster clinical and experimental neuroscientists who wish to share their discoveries about (1) early or predictable diagnosis; (2) the efficacy of an innovative therapy or a novel therapeutic regimen; and (3) the accurate prognosis of neuropsychiatric disorders that are supported by neuroimaging substrates. We welcome original articles, clinical or pre-clinical trial studies, and comprehensive reviews related (but not limited) to:

- Psychiatric neuroimaging;
- Advances of molecular imaging;
- Neuroimaging-informed phenotypes;
- Image-based neuropsychiatric diagnosis and prognosis;
- Drug delivery and pharmacological MRI;
- Translational psychiatry;
- Multimodal neuroimaging;
- Neuromodulation and neurostimulation;
- Personalized and complementary medicine;
- Computational psychiatry:
- Gut-brain interactions.

#### **Guest Editor**

Dr. Fabrício Pereira

- 1. Departments of Radiology and Psychiatry, University Hospital Center of Nimes, Nîmes, France
- 2. MIPA and Institute of Risk and Society, Nimes University, Nimes, France

#### Deadline for manuscript submissions

closed (15 June 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/127369

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).